Marinomed Biotech: Detailed clinical data show rapid onset of action of Budesolv to alleviate hay
Phase III study comparing Budesolv with standard treatment: Budesolv acts faster against allergic nasal symptoms and asthma-associated symptoms and requires 85% less active ingredient for the same effect.
By: Marinomed Biotech AG
As a summary, the data show that Budesolv is the first steroid nasal spray resulting in a clinically relevant reduction of symptoms – with approximately 50% of the maximum efficacy, within few hours after the first single treatment.
After one week of treatment low dose Budesolv was equally active compared with the originator product Rhinocort Aqua, which requires several days pre-treatment to be effective. Dr. Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed: "This study shows that thanks to our Marinosolv® technology, an aqueous solution of an active substance can be superior to a suspension. In addition, a significantly lower amount of active ingredient is required. This is excellent data, also with regard to our further projects based on the Marinosolv® technology, such as, for example, our product Tacrosolv, a treatment for allergic conjunctivitis and dry eye."
Reference link to detailed data:https://epostersonline.com/
Further information is available at: www.marinomed.com.
For further enquiries contact:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
T +43 (0)1 250 77 4460
Managing Partner, Metrum Communications
T +43 (0) 1 504 69 87 331